Yoh Watanabe

Primary chondrosarcoma of the ovary

AbstractOvarian heterologous sarcoma is a rare malignancy. Only three cases of ovarian chondrosarcoma have been reported in the literature, and almost all of these were components of ovarian teratomas. Herein, we report the clinicopathological characteristics of an ovarian chondrosarcoma in a 68‐year‐old woman who had previously undergone total hysterectomy. She had no subjective symptoms, and the tumor was unexpectedly found by further examination of osteoarthritis of the hip joint. Preoperative magnetic resonance imaging revealed curious findings of a lobulated high‐intensity component with a leaf‐vein‐like low‐intensity component. Computed tomography revealed irregularly distributed ossification extending to the entire tumor. Preoperative levels of CA125, CA19‐9, carcinoembryonic antigen, α‐fetoprotein, and lactic dehydrogenase were all within normal limits. Macroscopic findings of the surgically resected tumor and pathologic findings revealed no teratoma component in the tumor. Finally, we diagnosed the tumor as a primary chondrosarcoma of the ovary.

Current status of hereditary breast and ovarian cancer practice among gynecologic oncologists in Japan: a nationwide survey by the Japan Society of Gynecologic Oncology (JSGO)

The practices pertaining to hereditary breast and ovarian cancer (HBOC) in Japan have been rapidly changing owing to the clinical development of poly(ADP-ribose) polymerase inhibitors, the increasing availability of companion diagnostics, and the broadened insurance coverage of HBOC management from April 2020. A questionnaire of gynecologic oncologists was conducted to understand the current status and to promote the widespread standardization of future HBOC management. A Google Form questionnaire was administered to the members of the Japan Society of Gynecologic Oncology. The survey consisted of 25 questions in 4 categories: respondent demographics, HBOC management experience, insurance coverage of HBOC management, and educational opportunities related to HBOC. A total of 666 valid responses were received. Regarding the prevalence of HBOC practice, the majority of physicians responded in the negative and required human resources, information sharing and educational opportunities, and expanded insurance coverage to adopt and improve HBOC practice. Most physicians were not satisfied with the educational opportunities provided so far, and further expansion was desired. They remarked on the psychological burdens of many HBOC managements. Physicians reported these burdens could be alleviated by securing sufficient time to engage in HBOC management, creating easy-to-understand explanatory material for patients, collaboration with specialists in genetic medicine, and educational opportunities. Gynecologic oncologists in Japan are struggling to deal with psychological burdens in HBOC practice. To promote the clinical practice of HBOC management, there is an urgent need to strengthen human resources and improve educational opportunities, and expand insurance coverage for HBOC management.